Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies

Authors


  • Disclosure: Drs Cady and Martin have received research grants and honoraria from Merck & Co., Inc. Dr Mauskop has received honoraria from Merck & Co., Inc. Mr Rodgers, Ms Ramsey, and Drs Hustad and Skobieranda are employed by Merck & Co., Inc. and may own stock options in the company.

Roger Cady, Banyan Group, Inc., 3805 S. Kansas Expressway, Springfield, MO 65807, USA. Tel. + 1 417 841 3615, fax + 1 417 886 4498, e-mail rcady@banyangroupinc.com

Abstract

The presence of cutaneous allodynia may predict response to triptans. Identical randomized double-blind studies were conducted comparing the efficacy of rizatriptan 10 mg or placebo administered within 1 h of headache onset, while pain was mild. The primary endpoint was freedom from pain at 2 h. Presence of symptoms suggesting cutaneous sensitivity (SCS) at baseline and at 2 h post-treatment was recorded. Before treatment, 29% of rizatriptan patients and 22% of placebo patients reported SCS. At 2 h, the percentage of patients with SCS was significantly decreased with rizatriptan. The presence of SCS pre-treatment was not predictive of response to rizatriptan. Most patients with SCS at 2 h were non-responders. Early treatment with rizatriptan significantly reduced the percentage of patients with SCS at 2 h. The presence of SCS at baseline did not predict pain-free response, but presence of SCS at 2 h correlated with lack of a 2-h pain-free response.

Ancillary